Factive's potential value worths 244.3 billion won

Published: 2003-03-07 07:00:00

Updated: 2003-03-07 07:00:00

As the Advisory Committee of the US FDA consisting of outside experts recommended the approval of LG Life Sciences' novel fluoroquinolone antibiotic Factive through hearings on March 4, the FDA will be likely to approve the new drug in the early April according to the opinions of the influential ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK